Abstract 162P
Background
To evaluate clinical usefulness of hypofractionated radiotherapy (HRT) for pulmonary metastases from hepatocellular carcinoma (HCC) and investigate the prognostic factors affecting treatment outcome.
Methods
From March 2006 to May 2018, 58 patients with less than five pulmonary metastases from HCC who underwent HRT were analyzed retrospectively. Primary endpoint was treatment response rate. Secondary endpoints were progression-free survival, overall survival, prognostic factors affecting treatment outcomes and treatment-related side effects.
Results
The treatment response (complete and partial response) rate was 77.6 %, and the maximum treatment response was presented between 1 to 3 months after completion of HRT. The local control rate was 63.8 %. The median survival time was 16.3 months for all patients. The 1-year and 3-year overall survival rates were 79.3 % and 37.9 %, respectively. The median progression-free survival time was about 5 months and eighty-six percent of the patients (n = 50) showed post-treatment disease progression. Multivariate analysis identified the common prognostic factors for both OS and PFS as the planning target volume and maximal treatment response after HRT. The progression-free survival period was also a prognostic factor for OS in multivariate analysis. The grade 3 and 4 severe toxicities were reported in 4 and 3 patients, respectively.Table:
162P Prognostic factors
OS | PFS | |||||
---|---|---|---|---|---|---|
Median±SD* | p value† | Median±SD* | p value† | |||
Variable | (mo) | UVA | MVA | (mo) | UVA | MVA |
Age | 0.650 | 0.030 | 0.012 | |||
< 60 | 16.2±4.6 | 3.7±3.7 | ||||
≥ 60 | 21.4±7.9 | 4.9±1.3 | ||||
ECOG | 0.097 | 0.401 | ||||
0 | 44.3±17.2 | 8.0±3.0 | ||||
1, 2 | 16.3±4.5 | 3.7±1.3 | ||||
PTV size | 0.017 | 0.003 | 0.027 | 0.003 | ||
< 19 cc | 30.3±8.5 | 5.7±2.0 | ||||
≥ 19 cc | 11.5±2.1 | 3.0±0.3 | ||||
Type I max response | 0.013 | 0.000 | 0.029 | |||
CR+PR | 20.1±4.3 | 5.1±1.6 | ||||
SD+PD | 6.0±1.2 | 1.3±1.1 | ||||
Type II max response | 0.006 | 0.014 | 0.018 | |||
CR+PR+SD | 20.1±3.5 | 5.1±1.3 | ||||
PD | 4.6±1.8 | 1.2±0.1 | ||||
PFS period | 0.001 | 0.003 | ||||
< 5 mon | 10.6±3.5 | |||||
≥ 5 mon | 44.3±11.7 | |||||
Overall | 16.3±4.4 | 4.9±1.2 |
Conclusions
The considerable treatment outcome and acceptable toxicity may indicate clinical usefulness of HRT for patients who have less than five pulmonary metastases from HCC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
143P - NOTCH3 expression predicts poor survival in advanced esophageal squamous cell cancers
Presenter: Raja Pramanik
Session: Poster display session
Resources:
Abstract
144P - Severe hypovitaminosis D in metastatic gastric cancer patients from the Northern and Southern hemispheres: Data from the EXPAND phase III trial
Presenter: Radka Obermannova
Session: Poster display session
Resources:
Abstract
145P - Role of Glasgow prognostic score in chemo-naïve patients with advanced biliary tract cancer and good performance status
Presenter: Toshikazu Moriwaki
Session: Poster display session
Resources:
Abstract
146P - Anatomic versus non-anatomic resection for hepatocellular carcinoma: A meta-analysis of high-quality studies
Presenter: Bin Zhang
Session: Poster display session
Resources:
Abstract
147P - Clinical outcomes of proximal gastrectomy versus total gastrectomy for locally advanced proximal gastric cancer: a propensity score matching analysis
Presenter: Yingtai Chen
Session: Poster display session
Resources:
Abstract
148P - Efficacy of capecitabine and oxaliplatin versus S-1 as adjuvant chemotherapy in gastric cancer after D2 lymph node dissection according to lymph node ratio and N stage
Presenter: Seunghwan Lee
Session: Poster display session
Resources:
Abstract
150P - A Phase Ib Study of IMU-131 HER2/neu peptide vaccine plus chemotherapy in patients with HER2/neu overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction
Presenter: Yee Chao
Session: Poster display session
Resources:
Abstract
151P - Gene expression profiling for a better understanding of gastric cancer: From the perspective of metabolic rearrangement
Presenter: Midie Xu
Session: Poster display session
Resources:
Abstract
152P - Long-term outcomes of three-dimensional conformal radiotherapy-based and intensity-modulated radiotherapy-based concurrent chemoradiotherapy in patients with thoracic esophageal squamous cell carcinoma
Presenter: Chia-Lun Chang
Session: Poster display session
Resources:
Abstract
153P - Exosomal LINC00174 facilitates epithelial-mesenchymal transition in residual hepatocellular carcinoma after insufficient radiofrequency ablation by regulating c-JUN/MYCBP/c-Myc axis
Presenter: Dening Ma
Session: Poster display session
Resources:
Abstract